Core Insights - Changjiang Life Sciences Technology (00775.HK) announced the latest developments regarding its investment in Dogwood Therapeutics, Inc. (DWTX), a biopharmaceutical company focused on developing new drugs for pain relief and neuropathic symptoms, holding approximately 83% indirect equity in Dogwood [1] Group 1: Clinical Trial Results - Dogwood reported positive mid-term analysis results from its ongoing Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP), with 97 patients completing treatment [1] - The independent statistical review committee found a significant difference in pain improvement between patients treated with Halneuron® and those receiving a placebo during the four-week study [1] Group 2: Patient Demographics and Treatment Context - The average duration of CINP among patients in the mid-term analysis was 5 years, with 67% of eligible patients concurrently receiving stable doses of other chronic pain medications, including pregabalin, gabapentin, duloxetine, and opioids [2] - The overall dropout rate for the study was approximately 4.4%, significantly lower than the dropout rates of other FDA-approved chronic pain medications [2] Group 3: Future Expectations - Dogwood anticipates obtaining preliminary results from the Phase 2b trial by the third quarter of 2026, based on current recruitment speed and mid-term evaluation results [2] - The ongoing study is expected to provide approximately 80% to 85% statistical power to detect treatment differences for Halneuron® [2]
长江生命科技(00775.HK)：Halneuron®治疗化疗神经痛IIb期中期分析获积极信号